[Clinical significance and pathogenesis analysis of Moesin in multiple myeloma]. [PDF]
Gao YQ, Xu CL, Fu HY, Zhu TT, Chu JH.
europepmc +1 more source
Risk factors for multiple myeloma and its precursor diseases. [PDF]
Ma W, Zhao L, Zhou W.
europepmc +1 more source
[Research progress on targeted delivery of proteasome inhibitor nanoparticles for the treatment of multiple myeloma]. [PDF]
Lin YX, Jing DH, Mi JQ.
europepmc +1 more source
目的评价含泊马度胺全口服治疗方案二线治疗多发性骨髓瘤的疗效与安全性。方法回顾性分析2020年3月至2023年12月在我中心接受含泊马度胺全口服方案作为二线治疗的多发性骨髓瘤患者共22例,评价其疗效与安全性。结果22例患中位年龄为71.5岁,含泊马度胺的全口服二线治疗方案包括IPD 7例,PCD 11例, XPD 2例,PD 2例,中位治疗周期数为14,二线治疗ORR为63.64%,VGPR以上疗效为 36.36%。有来那度胺暴露史的13例患者中,ORR为53.85%, VGPR以上疗效为23.08 ...
肖洁 +7 more
doaj
High expression of VARS promotes the growth of multiple myeloma cells by causing imbalance in valine metabolism. [PDF]
Shi R +7 more
europepmc +1 more source
[Effect of different induction chemotherapy regimens on autologous hematopoietic stem cell mobilization in patients with multiple myeloma in the new drug era]. [PDF]
Wang XL +8 more
europepmc +1 more source
[The guidelines for diagnosis and treatment of myeloma bone disease in China (2022)]. [PDF]
Hematological Oncology Committee of China Anti-Cancer Association +2 more
europepmc +1 more source
[Prognostic value of circulating plasma cell in newly diagnosed multiple myeloma treated with bortezomib, lenalidomide, and dexamethasone]. [PDF]
Liu RR +6 more
europepmc +1 more source
[Multiple myeloma with chromothripsis: three cases report]. [PDF]
Wu CX +10 more
europepmc +1 more source
[The role and molecular mechanism of transcription factor EB and its target genes in multiple myeloma treatment with bortezomib]. [PDF]
Zhang RJ +8 more
europepmc +1 more source

